RRBSO has an important impact on breast cancer risk in this population; the 50 % reduction in breast cancer incidence associated with premenopausal RRBSO in high-risk women [49] would also need to be considered in these prospective studies before changing clinical practice for ovarian cancer prevention among BRCA1/2 mutation carriers. The gene discussed is BRCA1; the disease is ovarian carcinoma.